- Home
- FBRX
as 06-30-2025 12:31pm EST
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | DALLAS |
| Market Cap: | 84.0M | IPO Year: | N/A |
| Target Price: | $61.00 | AVG Volume (30 days): | 164.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.11 - $28.68 | Next Earning Date: | 08-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Forte Biosciences Inc. News
FBRX Breaking Stock News: Dive into FBRX Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Top Midday Decliners
MT Newswires
6 days ago
Top Premarket Decliners
MT Newswires
6 days ago
Forte Biosciences Prices $75 Million Share Offering
Business Wire
6 days ago
Forte Biosciences Announces Pricing of $75 Million Public Offering
MT Newswires
6 days ago
Forte Biosciences Starts Public Offering
Business Wire
6 days ago
Forte Biosciences Announces Proposed Public Offering
TipRanks
6 days ago
Forte Biosciences announces data from trial in celiac disease for FB102
Business Wire
8 days ago
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study
Compare FBRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FBRX Forte Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.